INTS

Intensity Therapeutics, Inc. Common stock

NASDAQ: INTS · HEALTHCARE · BIOTECHNOLOGY

$4.88

-5.51% today

Updated 2026-06-05

Market cap

$10.60M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.01

Dividend yield

—

52W range

$4 – $44

Volume

0.0M

Market cap

$10.60M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.01

Dividend yield

—

52W range

$4 – $44

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target

$24.80

+408.20%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-1.83M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-7.58M	$-10.54M	$-16.27M	$-11.61M	$-2.43M
EPS	—	—	—	—	$-4.01
Free cash flow	$-5.48M	$-7.21M	$-15.22M	$-9.23M	$-1.83M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
INTS	$10.60M	23	4.3	3.0	5.0	7.3	—	Avoid
LLY	$1.01T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$567.28B	57	4.7	9.0	3.3	6.0	-67.79%	Buy
ABBV	$391.50B	63	4.0	8.0	4.0	5.0	-48.06%	Buy
UNH	$373.28B	54	5.3	5.5	4.0	5.5	-26.94%	Buy
NVS	$289.19B	49	3.3	9.0	3.3	4.5	-65.15%	Hold

Smart narrative

Intensity Therapeutics, Inc. Common stock trades at $4.88. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Intensity Therapeutics, Inc. Common stock's stock price?

Intensity Therapeutics, Inc. Common stock (INTS) trades at $4.88.

Is Intensity Therapeutics, Inc. Common stock overvalued?

Intensity Therapeutics, Inc. Common stock carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Intensity Therapeutics, Inc. Common stock (INTS)?

The 12-month analyst consensus target is $24.80, about 408.2% above the current $4.88. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.intensitytherapeutics.com

Quick metrics

P/S ratio—

ROE-107.16%

Beta3.06

50D MA$4.71

200D MA$7.68

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

INTS vs LLY →INTS vs JNJ →INTS vs ABBV →Stock screener →